ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety.
about
Long-term opioid treatment of chronic nonmalignant pain: unproven efficacy and neglected safety?Systematic literature review and meta-analysis of the efficacy and safety of prescription opioids, including abuse-deterrent formulations, in non-cancer pain managementMarketed New Drug Delivery Systems for Opioid Agonists/Antagonists Administration: A Rapid OverviewOpioid formulations with sequestered naltrexone: a perspective review.The Clinical Applications of Extended-Release Abuse-Deterrent Opioids.Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendationsEffects of concurrent intravenous morphine sulfate and naltrexone hydrochloride on end-tidal carbon dioxideAbuse-deterrent formulations, an evolving technology against the abuse and misuse of opioid analgesics.Update on prescription extended-release opioids and appropriate patient selection.Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users.Morphine sulfate and naltrexone hydrochloride extended release capsules for the management of chronic, moderate-to-severe pain, while reducing morphine-induced subjective effects upon tampering by crushing.Abuse-deterrent and tamper-resistant opioids: how valuable are novel formulations in thwarting non-medical use?Assessment of extended-release opioid analgesics for the treatment of chronic pain.Sequestered naltrexone in sustained release morphine or oxycodone - a way to inhibit illicit use?End-of-dose pain in chronic pain: does it vary with the use of different long-acting opioids?Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations.Abuse-Deterrent Opioid Formulations: Pharmacokinetic and Pharmacodynamic Considerations.Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain.Experience with an extended-release opioid formulation designed to reduce abuse liability in a community-based pain management clinic.Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain.The implications of tamper-resistant formulations for opioid rotation.Assessment of pharmacodynamic effects following oral administration of crushed morphine sulfate and naltrexone hydrochloride extended-release capsules compared with crushed morphine sulfate controlled-release tablets and placebo in nondependent recrExtending Time Profile of Morphine-Induced Analgesia Using a Chitosan-Based Molecular Imprinted Polymer Nanogel.
P2860
Q24598228-9C09C3BF-C0FB-4BF1-8C90-F776C19512CDQ26853312-D75706F3-CA11-46E3-ADCA-DB133B2CC8F0Q28079382-B5F56AFC-4A76-4CE8-AA25-8D46DC8386FAQ33949447-A6DD4580-B018-401D-AE2F-C5BF0ED724ACQ34530594-F9AC350F-6C72-4D53-9891-D766E20E5DA0Q35846608-94A507E3-497D-4911-A522-1A5654C3D525Q35925351-605B3D0C-DBEE-4AA8-8855-ACE2F734C503Q36549049-42404572-0A93-4282-8683-5487BDF31632Q37053718-8E9A88AF-A69B-436D-8FB0-26D9FDCF6395Q37265572-1D2B3E61-6F62-4D92-83E5-9DDD8C5083AAQ37862258-F04C64DF-55FF-4F3E-99A9-BA7AFB3A837AQ38068507-A6A909BB-FCC6-4402-80F8-9810BF095122Q38092855-6E253C53-AF83-4F5D-B3AE-0C017D9E8AC9Q38160935-48BBB5EC-91B0-4F47-8486-5E2D0DC3886FQ38174282-5D430910-1180-44C0-BB5F-880A49C2CD9DQ38632934-EB973292-FB17-46D5-B7FE-B0CD4E66A398Q38683620-BDF6F002-95CF-426D-A80A-54384CDAAB72Q38799636-AAB916CA-E663-4E40-A561-B1F57276B870Q38905036-799CED3C-D516-424E-BAFC-FD9EE248A0EBQ42950103-A474FDCB-4F77-4F85-87F5-2B320FEDA087Q44336529-79675CEB-EBE0-4662-878D-0CAD501C3CCEQ44339796-092D2561-B0D5-4E83-9656-84905C978857Q47744308-44FD777D-BEBA-46FD-A560-939C7B35341F
P2860
ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
ALO-01 (morphine sulfate and n ...... inetics, efficacy, and safety.
@en
ALO-01 (morphine sulfate and n ...... inetics, efficacy, and safety.
@nl
type
label
ALO-01 (morphine sulfate and n ...... inetics, efficacy, and safety.
@en
ALO-01 (morphine sulfate and n ...... inetics, efficacy, and safety.
@nl
prefLabel
ALO-01 (morphine sulfate and n ...... inetics, efficacy, and safety.
@en
ALO-01 (morphine sulfate and n ...... inetics, efficacy, and safety.
@nl
P2093
P921
P1433
P1476
ALO-01 (morphine sulfate and n ...... inetics, efficacy, and safety.
@en
P2093
Franklin Johnson
Joseph Stauffer
Nathaniel Katz
Stephen Sun
P304
P356
10.1016/J.JPAIN.2009.07.017
P577
2009-11-27T00:00:00Z